medigraphic.com
ISSN 1561-2929 (Print)

2015, Number 1

<< Back Next >>

RCAN 2015; 25 (1)

Waist circumference, size of visceral fat and metabolic disorders in morbid obesity

Martínez CM, Barceló AM, Gómez GR, Ramírez BD

Language: Spanish
References: 87
Page: 28-47
PDF size: 690.78 Kb.


ABSTRACT

Rationale: Obesity has become a worldwide epidemic. Body weight excess affects one-third of the Cuban population. Anatomical distribution of the excess of body fat might serve to establish metabolic risk factors and to determine comorbidities. Objective: To assess if waist circumference is associated with visceral fat and occurrence of metabolic disorders in morbidly obese subjects (Body Mass Index ≥ 40 Kg.m-2). Material and method: Associations between size of visceral fat (measured by electric bioimpedance), waist circumference, peripheral utilization of glucose, fasting serum insulin, HOMA index, sera triglycerides and cholesterol were cross-sectionally assessed in 52 morbidly obese subjects (Women: 67.2%; Ages ≥ 60 years: 3.9%; High Blood Pressure: 76.9%; Diabetes mellitus: 7.7%) ambulatorily assisted at the “Hermanos Ameijeiras” Hospital (Havana City, Cuba). Results: Seventy-one point one percent of the studied morbidly obese subjects showed ≥ 10 kilograms of visceral fat. Size of visceral fat was independent from waist circumference, BMI, the state of peripheral utilization of glucose, presence of insulin resistance, and sera lipid fractions concentrations. Likewise, size of visceral fat was independent from the presence of the Metabolic Syndrome. Conclusions: In morbid obesity, occurrence of disorders in the peripheral utilization of glucose, presence of insulin resistance, state of sera lipid fractions and existence of Metabolic Syndrome are independent from the size of visceral fat. Others topographical locations of body fat (such as intra-parenchymatous fat) might have a higher impact upon body energy metabolism.


REFERENCES

  1. Haidar YM, Cosman BC. Obesity epidemiology. Clin Colon Rectal Surg 2011;24:205-10.

  2. Imes CC, Burke LE. The obesity epidemic: The United States as a cautionary tale for the rest of the world. Curr Epidemiol Rep 2014;1:82-8.

  3. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009 – 2010. NCHS Data Brief 2012;82:1-8.

  4. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991 – 1998. JAMA 1999; 282:1519-22.

  5. Peña M, Bacallao J. La obesidad y sus tendencias en la región. Rev Panam Salud Pública 2001;10:45-78.

  6. Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutrition Rev 2012;70:3-21.

  7. Gutiérrez Fisac JL, Regidor E, López García E, Banegas Banegas JR, Rodríguez Artalejo F. The obesity epidemic and related factors: The case of Spain. Cadernos Saúde Pública 2003;19: S101-S110.

  8. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.

  9. Jiménez Acosta S, Rodríguez Suárez A, Díaz Sánchez ME. La obesidad en Cuba. Una mirada a su evolución en diferentes grupos poblacionales. RCAN Rev Cubana Aliment Nutr 2013;23:297-308.

  10. Bays HE. Adiposopathy. Is “sick fat” a cardiovascular disease? J Am Coll Cardiol 2011;57:2461-73.

  11. Blüher M. Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Prac Res Clin Endocr Metab 2013;27:163-77.

  12. Blüher M. Adipose tissue dysfunction in obesity. Experim Clin Endocr Diabetes 2009;117: 241-50.

  13. Lavie CJ, McAuley PA, Church TS, Milani RV, Blair SN Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. J Am Coll Cardiol. 2014;63:1345-54.

  14. Sturm R, Hattori A. Morbid obesity rates continue to rise rapidly in the United States. Int J Obesity 2013;37:889-91.

  15. Arterburn DE, Maciejewski ML, Tsevat, J. Impact of morbid obesity on medical expenditures in adults. Int J Obes 2005; 29:334-9.

  16. Bouchard C, Bray GA, Hubbard VS. Basic and clinical aspects of regional fat distribution. Am J Clin Nutr 1990;52: 946-50.

  17. Enzi G, Gasparo M, Biondetti PR, Fiore D, Semisa M, Zurlo F. Subcutaneous and visceral fat distribution according to sex, age, and overweight, evaluated by computed tomography. Am J Clin Nutr 1986;44:739-46.

  18. Tchoukalova YD, Koutsari C, Karpyak MV, Votruba SB, Wendland E, Jensen MD. Subcutaneous adipocyte size and body fat distribution. Am J Clin Nutr 2008;87:56-63.

  19. Booth A, Magnuson A, Foster M. Detrimental and protective fat: body fat distribution and its relation to metabolic disease. Horm Mol Biol Clin Investig 2014;17:13-27.

  20. Walker GE, Marzullo P, Ricotti R, Bona G, Prodam F. The pathophysiology of abdominal adipose tissue depots in health and disease. Horm Mol Biol Clin Investig 2014;19:57-74.

  21. Hamdy O, Porramatikul S, Al-Ozairi E. Metabolic obesity: The paradox between visceral and subcutaneous fat. Current Diabetes Reviews 2006;2:367-73.

  22. Matsuzawa Y. The role of fat topology in the risk of disease. Int J Obes 2008;32 (Suppl 7):S83-S92.

  23. Revelo XS, Luck H, Winer S, Winer DA. Morphological and inflammatory changes

  24. in visceral adipose tissue during obesity. Endocr Pathol 2014;25:93-101.

  25. Pischon T, Boeing H, Hoffman K, Bergmann M, Schulze MB, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008;359: 2105-20.

  26. Eglit T, Rajasalu T, Lember M. Metabolic syndrome in Estonia: Prevalence and associations with insulin resistance. Int J Endocrinol 2012;2012: 951672.

  27. Walker SP, Rimm EB, Ascherio A, Kawachi I, Stampfer MJ, Willett WC. Body size and fat distribution as predictors of stroke among US men. Am J Epidemiol 1996;144:1143-50.

  28. Nicklas BJ, Cesari M, Penninx BW, Kritchevsky SB, Ding J, Newman A, et al. Abdominal obesity is an independent risk factor for chronic heart failure in older people. J Am Geriatr Soc 2006; 54:413-20.

  29. Ryo M, Funahashi T, Nakamura T, Kihara S, Kotani K, Tokunaga K, et al. Fat accumulation and obesity-related cardiovascular risk factors in middle-aged Japanese men and women. Int Med 2014;53:101-5.

  30. Foster MC, Hwang SJ, Massaro JM, Hoffmann U, DeBoer IH, Robins SJ, et al. Association of subcutaneous and visceral adiposity with albuminuria: The Framingham Heart Study. Obesity [Silver Spring] 2011;19:1284-9.

  31. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-51.

  32. Berings M, Wehlou C, Verrijken A, Deschepper E, Mertens I, Kaufman JM, et al. Glucose intolerance and the amount of visceral adipose tissue contribute to an increase in circulating triglyceride concentrations in Caucasian obese females. PloS One 2012);7(9):e45145.

  33. Blüher M. Clinical relevance of adipokines. Diab Metab J 2012;36: 317-27.

  34. Harwood HJ Jr. The adipocyte as an endocrine organ in the regulation of metabolic homeostasis. Neuropharmacology 2012;63:57-75.

  35. Santana Porbén S. Las adipocitoquinas en la génesis y evolución del síndrome metabólico. RCAN Rev Cubana Aliment Nutr 2010;20:304-17.

  36. Müller MJ, Lagerpusch M, Enderle J, et al. Beyond the body mass index: Tracking body composition in the pathogenesis of obesity and the metabolic syndrome. Obes Rev 2012;13(Suppl 2): 6-13.

  37. Seidell JC. Waist circumference and waist/hip ratio in relation to all-cause mortality, cancer and sleep apnea. Eur J Clin Nutr 2010;64:35-41.

  38. Zazai R, Wilms B, Ernst B, Thurnheer M, Schultes B. Waist circumference and related anthropometric indices are associated with metabolic traits in severely obese subjects. Obes Surg 2014; 24:777-82.

  39. Xu LI, Katashima M, Yasumasu T, Li KJ. Visceral fat area, waist circumference and metabolic risk factors in abdominally obese Chinese adults. Biomed Environm Sci 2012;25:141-8.

  40. Janssen I, Heymsfield S, Allison D, Kotler D, Ross R. Body mass index and waist circumference, waist-to-hip ratio and body mass index as indication of cardiovascular risk factors: The Canadian Health Surveys. Int J Obes Relat Metab Disord 2001;25:652-61.

  41. Maffeis C, Pietrobelli A, Grezzani A, Provera S, Tato L. Waist circumference and cardiovascular risk fators in prepuberal children. Obes Res 2001;9: 179-8.

  42. Sagun G, Oguz A, Karagoz E, Filizer AT, Tamer G, Mesci B. Application of alternative anthropometric measurements to predict metabolic syndrome. Clinics [Sao Paulo] 2014;69:347-53.

  43. Diniz Araújo ML, Coelho Cabral P, Kruze Grande de Arruda I, Siqueira Tavares Falcão AP, Silva Diniz A. Body fat assessment by bioelectrical impedance and its correlation with anthropometric indicators. Nutrición Hospitalaria [España] 2012;27:1999-2005.

  44. Ozhan H, Alemdar R, Caglar O, Ordu S, Kaya A, Albayrak S; for the MELEN Investigators. Performance of bioelectrical impedance analysis in the diagnosis of metabolic syndrome. J Invest Med 2012;60:587-91.

  45. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013;36(Suppl 1):S67-S74.

  46. Weiner JA, Lourie JA. Practical Human Biology. Academic Press. London: 1981.

  47. Lohman TG, Roche A, Martorell R. Anthropometric standardization reference manual. Human Kinetics Books. Primera Edición. Champaign, Illinois: 1988.

  48. Waterlow JC. Classification and definition of protein-calorie malnutrition. Br Med J 1972;3(5826):566-9.

  49. WHO Working Group. Use and interpretation of anthropometric indicators of nutritional status. Bulletin of the World Health Organization 1986; 64:929-41.

  50. Díaz Sánchez ME. Manual de Antropometría para el trabajo en Nutrición. Instituto de Nutrición e Higiene de los Alimentos. Segunda Edición. Ciudad Habana: 1999.

  51. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999;130: 461-70.

  52. Pathania M, Rathaur VK, Yadav N, Jayara A, Chaturvedi A. Quantitative micro-albuminuria assessment from “random voided urinary albumin:creatinine ratio” versus “24 hours urinary albumin concentration” for screening of diabetic nephropathy. J Clin Diagn Res 2013;7:2828-31.

  53. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment. Diabetologia 1985;28:412-19.

  54. WHO World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. Geneva: 1999. Disponible en: Available from: http://www.whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf.

  55. Santana Porbén S, Martínez Canalejo H. Manual de Procedimientos Bioestadísticos. Segunda Edición. EAE Editorial Académica Española. ISBN-13: 9783659059629. ISBN-10: 3659059625. Madrid: 2012.

  56. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 2000;284:3043-5.

  57. Bray GA. Obesity: Historical development of scientific and cultural ideas. Int J Obes Relat Metab Disord 1990;14:909-26.

  58. Jeffcoale W. Obesity is a disease: Food for thought [Editorial]. Lancet 1998; 351:903-4.

  59. Martínez JA, Kearney JM, Kafatos A, Paquet S, Martínez González MA. Variables independently associated with self-reported obesity in the European Union. Public Health Nutr 1999;2:125-33.

  60. Berghöfer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, Willich SN. Obesity prevalence from a European perspective: a systematic review. BMC Public Health 2008;8(1):200.

  61. Kral JG. Morbid obesity and related health risks. Ann Intern Med 1985;103(6 Part 2):1043-7.

  62. Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 2006;29: 109-17.

  63. Reilly JJ, Methven E, McDowell ZC, Hacking B, Alexander D, Stewart L, Kelnar CJ. Health consequences of obesity. Arch Dis Child 2003;88:748-52.

  64. Cohen-Mansfield J, Perach R. Is there a reversal in the effect of obesity on mortality in old age? J Aging Res 2011; 2011:765071.

  65. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998;338:1-7.

  66. Kennedy RL, Chokkalingham K, Srinivasan R. Obesity in the elderly: Who should we be treating, and why, and how? Curr Op Clin Nutr Metab Care 2004;7: 3-9.

  67. Thakur V, Richards R, Reisin E. Obesity, hypertension and the heart. Am J Med Sci 2001;321:242-8.

  68. Ferri C, Desideri G, Valenti M, Bellini C, Pasin M, Santucci A, De Mattia G. Early up-regulation of endothelial adhesion molecules in obese hypertensive men. Hypertension 1999;34:568-73.

  69. Pontiroli AE, Pizzocri P, Koprivec D, Vedani P, Marchi M, Arcelloni C, et al. Body weight and glucose metabolism have a different effect on circulating levels of ICAM-1, E-selectin, and endothelin-1 in humans. Eur J Endocrinol 2004;150:195-200.

  70. Van Gaal LF, Mertens IL, Christophe E. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444 (7121):875-80.

  71. Savoia C, Schiffrin E. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci 2007; 112:375-84.

  72. Korsić M, Fister K, Ivanković D, Jelcić J. Visceral obesity. Lijec Vjesn 2011;133(7-8):284-7.

  73. Sethi JK, Vidal-Puig A. Visfatin: The missing link between intra-abdominal obesity and diabetes? Trends Molecular Medicine 2005;11:344-7.

  74. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007;56:1010-3.

  75. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease. Diabetes 1997;46:860-7.

  76. Després JP. Dyslipidaemia and obesity. Baillieres Clin Endocrinol Metab 1994; 8:629-60.

  77. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444(7121):881-7.

  78. Després JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, et al. Abdominal obesity and the metabolic syndrome: Contribution to global cardio-metabolic risk. Arteriosclerosis Thromb Vasc Biol 2008;28:1039-49.

  79. Blüher M. Are there still healthy obese patients? Curr Opin Endocr Diab Obesity 2012;19:341-6.

  80. Wei Ch, Ranson L, Davidson L, Adams T, Gress R, Hunt S, et al. Metabolically healthy severe obesity and cardiovascular disease risk: A 6-year longitudinal prospective study. J Am Coll Cardiol 2014;63:A1353-A1361.

  81. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Nat Acad Sci 2009;106: 15430-5.

  82. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010;42:320-30.

  83. Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 2009;42:1331-46.

  84. Hiratsuka A, Adachi H, Fujiura Y, Yamagishi SI, Hirai Y, Enomoto M, et al. Strong association between serum hepatocyte growth factor and metabolic syndrome. J Clin Endocrinol Metab 2005; 90:2927-31.

  85. Aller R, Izaola O, Ruiz Rebollo L, Pacheco D, De Luis Román DA. Predictive factors of non-alcoholic steatohepatitis: Relationship with metabolic syndrome. Nutrición Hospitalaria [España] 2015;31:2496-2502.

  86. Guo SS, Zeller C, Chumlea WC, Siervogel RM. Aging, body composition, and lifestyle: The Fels Longitudinal Study. Am J Clin Nutr 1999;70:405-11.

  87. Baumgartner RN, Stauber PM, McHugh D, Koehler KM, Garry PJ. Cross-sectional age differences in body composition in persons 60+ years of age. J Gerontology 1995;50:M307-M316.




2020     |     www.medigraphic.com